Concord Biotech Limited — Investor Meet, 18-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Concord Biotech's Q1 FY26 revenue dipped 5% to INR 204 Cr due to business lumpiness. PAT fell to INR 44 Cr, with EBITDA margins at 30.1%. This was largely due to ~INR 12-13 Cr in start-up costs for their new Valthera injectable facility; excluding this, margins remained ~37%. The company secured US FDA approval for teriflunomide and passed other key inspections. Strategic moves include launching CDMO sales in Q2 FY26 with an innovator client (targeting $40-50M opportunity), and establishing new US and India subsidiaries. Management is confident in long-term growth, driven by product pipeline and market expansion.